Zai Lab Stock Overlap Studies Bollinger Bands
| ZLAB Stock | USD 18.37 -0.50 -2.65% |
| Symbol |
This analysis covers thirty-eight data points across the selected time horizon. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Zai Lab middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Zai Lab. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Zai Lab Technical Analysis Modules
Most technical analysis of Zai Lab help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Zai from various momentum indicators to cycle indicators. When you analyze Zai charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Stock Overview, Methodology & Data Sources
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China. Zai Lab operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1951 people. The stock overview for Zai Lab summarizes business drivers, financial profile, and market behavior. The company is positioned within Cancer Fighters. Current metrics include P/B of 2.84, profit margin of -38.15%. Zai Lab has a market cap of 2.03 B, ROE of -22.56%.
Methodology
Unless otherwise specified, financial data for Zai Lab is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Zai (USA Stocks:ZLAB) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Datasets used in this report incorporate public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR. Information may be standardized across formats and may reflect delayed updates. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Zai Lab may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Ellen Johnson - Member of Macroaxis Editorial BoardBe your own money manager
Performance tracking around Zai Lab should go beyond the latest gain or loss and focus on how the position changes overall portfolio efficiency over time. A disciplined tracking process turns performance data into better decisions instead of more noise.
Generate Optimal Portfolios
Align your risk and return expectations
More Resources for Zai Stock Analysis
Understanding Zai Lab typically begins with financial statements and long-term trend review. Financial ratios provide a structured lens for assessing Zai Lab's profitability and growth trends. Below are reports that help frame Zai Lab Stock in context:Zai Lab has a market cap of 2.03 B, operating margin of -54.4%, ROE of -22.56%. Your Current Watchlist can help frame allocation decisions. This suggests a position in Zai Lab inside the allocation mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Zai Stock refer to our How to Trade Zai Stock guide.Zai Lab currently shows ROE of -22.56%, market cap of 2.03 Billion. Zai Lab analysis should be paired with portfolio risk and diversification tools before adjusting allocations. Within the Healthcare space, Zai Lab peer comparison and risk tools below help frame relative strengths and weaknesses. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Market capitalization and book value offer complementary views of Zai Lab - the first driven by investor sentiment, the second by accounting standards. Zai Lab's market capitalization is 2.03 B. At P/B 2.84, Zai Lab trades moderately above book value. Enterprise value stands at 1.56 B. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
Note that Zai Lab's intrinsic value and market price are different measures derived from different inputs. For Zai Lab, key inputs include a P/B ratio of 2.84, a profit margin of -38.15%, ROE of -22.56%, and revenue of 460.16 M. Zai Lab market price reflects the current exchange level formed by active bids and offers.